Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback